<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To observe the effects of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> on urinary sediment podocalyxin and monocyte chemoattractant protein-1 (<z:chebi fb="17" ids="50099">MCP</z:chebi>-1) excretion in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and to explore its possible renoprotective mechanisms </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Ninety-eight patients with uncontrolled type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, who were previously prescribed <z:chebi fb="0" ids="6801">metformin</z:chebi>, <z:chebi fb="0" ids="2376">acarbose</z:chebi>, or both, were randomly assigned to a DP group (add-on <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>; n = 49) or a DS group (add-on <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi>; n = 49) </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: After 12 weeks of treatment, both add-on <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> therapy (the DP group) and add-on <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> therapy (the DS group) demonstrated a similar improvement in fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> A1c, but systolic and diastolic blood pressure declined significantly in only the DP group </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, the DP group showed significantly better efficacy in reducing urinary <z:chebi fb="17" ids="50099">MCP</z:chebi>-1 excretion in comparison with the DS group </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, both urinary albumin and urinary sediment podocalyxin excretion decreased significantly in the DP group but not in the DS group </plain></SENT>
<SENT sid="5" pm="."><plain>The urinary sediment podocalyxin to <z:chebi fb="0" ids="16737">creatinine</z:chebi> ratio had a positive correlation with urinary albumin to <z:chebi fb="0" ids="16737">creatinine</z:chebi> ratio (r = 0.624; P&lt;.01) and urinary <z:chebi fb="17" ids="50099">MCP</z:chebi>-1 to <z:chebi fb="0" ids="16737">creatinine</z:chebi> ratio (r = 0.346; P&lt;.01) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> treatment revealed a podocyte-protective capacity in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and the underlying mechanisms may be partly attributed to its effective suppression of excessive local <z:mp ids='MP_0001859'>renal inflammation</z:mp> </plain></SENT>
</text></document>